Cyclin-Dependent Kinase 2
"Cyclin-Dependent Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A key regulator of CELL CYCLE progression. It partners with CYCLIN E to regulate entry into S PHASE and also interacts with CYCLIN A to phosphorylate RETINOBLASTOMA PROTEIN. Its activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P27 and CYCLIN-DEPENDENT KINASE INHIBITOR P21.
| Descriptor ID |
D051357
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.646.500.750 D12.644.360.250.323 D12.776.167.200.323 D12.776.476.250.323
|
| Concept/Terms |
Cyclin-Dependent Kinase 2- Cyclin-Dependent Kinase 2
- Cyclin Dependent Kinase 2
- Cdk2 Protein Kinase
- Cdc2-Related Protein Kinase
- Cdc2 Related Protein Kinase
- p33cdk2 Kinase
- CDK2 Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 2".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase 2" by people in this website by year, and whether "Cyclin-Dependent Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 6 | 6 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 6 | 6 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 6 | 6 |
| 2001 | 0 | 7 | 7 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 9 | 9 |
| 2004 | 0 | 9 | 9 |
| 2005 | 0 | 10 | 10 |
| 2006 | 5 | 0 | 5 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 4 | 6 |
| 2009 | 4 | 3 | 7 |
| 2010 | 2 | 4 | 6 |
| 2011 | 3 | 3 | 6 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 1 | 5 |
| 2014 | 1 | 1 | 2 |
| 2015 | 4 | 1 | 5 |
| 2016 | 3 | 0 | 3 |
| 2017 | 3 | 2 | 5 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 0 | 3 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase 2" by people in Profiles.
-
CDK2 inhibition disorders centrosome stoichiometry and alters cellular outcomes in aneuploid cancer cells. Cancer Biol Ther. 2023 12 31; 24(1):2279241.
-
Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. Oncogene. 2022 Dec; 41(50):5331-5346.
-
Robust designation of meiotic crossover sites by CDK-2 through phosphorylation of the MutS? complex. Proc Natl Acad Sci U S A. 2022 05 24; 119(21):e2117865119.
-
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Mol Cancer Ther. 2021 03; 20(3):477-489.
-
Development of CDK2 and CDK5 Dual Degrader TMX-2172. Angew Chem Int Ed Engl. 2020 08 10; 59(33):13865-13870.
-
Cell Cycle-Dependent Switch of TopBP1 Functions by Cdk2 and Akt. Mol Cell Biol. 2020 03 30; 40(8).
-
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019 11 08; 10(1):5114.
-
Absence of cyclin-dependent kinase inhibitor p27 or p18 increases efficiency of iPSC generation without induction of iPSC genomic instability. Cell Death Dis. 2019 03 20; 10(4):271.
-
Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res. 2018 10 01; 78(19):5481-5491.
-
GSK-3 promotes S-phase entry and progression in C. elegans germline stem cells to maintain tissue output. Development. 2018 05 14; 145(10).